The association between menopause and the kidney status is consistent with data from an epidemiological study revealing that postmenopausal women are susceptible to chronic kidney disease, which is characterized by diabetic nephropathy, hypertension, and central obesity
While cost and insurance coverage remain the leading reasons why consumers have stopped taking a GLP-1 medication, that percentage is down from early April data
Products that combine glutathione with complementary ingredients like milk thistle, selenium, or vitamin C can offer enhanced benefits, but the amounts of each ingredient should still be clearly disclosed
Also, the sphingomyelin input (upper right corner in the diagram below) is 30% higher in females
Bottom line: Your GLP-1 medication is a powerful tool for metabolic health
While the FDA recently approved the first generic version of Victoza , or liraglutidea first-generation GLP-1 that has been on the FDA's shortage list since 2023demand for the once-daily injection has waned as patients move to more effective once-weekly treatments like Ozempic and Mounjaro
